Morning Glory Sciences– Author –
After completing graduate school, I studied at a Top tier research hospital in the U.S., where I was involved in the creation of treatments and therapeutics in earnest. I have worked for several major pharmaceutical companies, focusing on research, business, venture creation, and investment in the U.S. During this time, I also serve as a faculty member of graduate program at the university.
-
Biotech Investment News: Major Pharmaceutical Deals of Boehringer Ingelheim (2015–2025)
Strategic Review: Diversifying into Oncology and Immunology Through Innovative Partnerships Boehringer Ingelheim (BI), traditionally strong in cardiovascular and respiratory areas, has pivoted towards oncology and immune diseases over th... -
Rare & Pediatric Disease News Vol.3: Are Adult Cancer Drugs Really Enough for Children?
Why Pediatric Oncology Requires Tailored Innovation From infancy to adulthood, the human body undergoes approximately two decades of dynamic growth. A newborn weighing 3,000 grams grows tenfold or more. Throughout this period, the endocr... -
[Science News] Cancer Discovery Spotlight: CAFs Suppress NK Cells to Promote Breast Cancer Metastasis
A study published in the June 2025 issue of Cancer Discovery reveals how cancer-associated fibroblasts (CAFs) promote metastatic progression in breast cancer by suppressing natural killer (NK) cell cytotoxicity. This work was selected fo... -
Biotech Investment News: Amgen’s Key Deals from 2015 to 2025
Strategic Review: From Biologics to Rare Diseases, Oncology, and RNA Innovation Over the past decade, Amgen has expanded beyond its legacy focus on bone and inflammatory diseases to invest heavily in oncology, RNA therapies, and rare dis... -
Biotech Investment News: Novartis’s Key Deals from 2015 to 2025
Strategic Review: From Blockbusters to Nuclear Medicine, Gene and Cell Therapy Over the past decade, Novartis has strategically shifted its focus toward high-value therapies, including nuclear medicine (Pluvicto), gene therapy (Zolgensma... -
【Biotech Investment News】Sanofi’s Strategic Deals in 2025: A Comprehensive Summary
Key Pharma Moves: Sanofi’s Acquisitions and Collaborations in Q1–Q3 2025 In 2025, Sanofi has executed several key strategic acquisitions and licensing deals focused on immunology, neurology, and rare diseases. Here's a summary of these d... -
Biotech Investment News: Eli Lilly’s Key Deals from 2015 to 2025
Strategic Overview: Dominance in Diabetes and Obesity with Oncology Expansion Eli Lilly has strengthened its global leadership in diabetes and obesity while expanding into oncology, neuroscience, and gene therapy. With the blockbuster su... -
Biotech Investment News: GSK’s Major Deals from 2015 to 2025
Strategic Review: Focused Expansion in Vaccines and Specialty Medicines Over the past decade, GSK has shifted from large-scale M&A to focused investments and strategic partnerships, particularly in vaccines, oncology, respiratory, an... -
Biotech Investment News: AstraZeneca’s 10-Year Deal Overview & 2025 Update (2015–2025)
Strategic Review: Investing in ADCs, Rare Diseases, and Biomanufacturing Capabilities AstraZeneca has expanded significantly in oncology through antibody and ADC partnerships, including a high-profile collaboration with Japan’s Daiichi S... -
[Science News] KRAS Inhibition and T-cell Dependency: Defining the Immune Role in Pancreatic Cancer Therapy (Cancer Discovery Summary / With My Thoughts)
A study published online in June 2025 in Cancer Discovery reveals that **T-cell–dependent tumor regression** is a key mechanism underlying the efficacy of KRAS G12D inhibitors in pancreatic ductal adenocarcinoma (PDAC). KRAS G12D is a ma... -
[Aging & Rejuvenation Science Series #2] GLP-1R Agonists May Mitigate Alzheimer’s via Energy Regulation: Insights from Nature Aging
In a May 2025 Nature Aging publication, Zhang and colleagues report that GLP-1 receptor agonists (GLP-1R agonists), widely used in the treatment of type 2 diabetes, may also alleviate Alzheimer’s disease (AD) symptoms in mice. Key Findin... -
Biotech Investment News: AbbVie’s Major Deals from 2015 to 2025
Strategic Review: Diversifying Beyond Humira AbbVie has proactively diversified its portfolio beyond Humira, expanding into oncology, neuroscience, immunology, ophthalmology, and aesthetics. Its acquisition of Allergan, ADC platforms, an... -
Biotech Investment News: Bristol Myers Squibb’s Major Deals (2015–2025)
Strategic Review: From Opdivo to Next-Gen Modalities BMS is known as a pioneer in immuno-oncology, with the development of Opdivo (nivolumab) and Yervoy (ipilimumab). Over the past decade, the company has expanded aggressively into new m... -
Biotech Investment News: Roche’s Major Deals Over the Past Decade (2015–2025)
Strategic Review: Expanding from Monoclonal Antibodies into Diagnostics, RNA, and Cell Therapy Roche has long been a global leader in monoclonal antibody-based cancer therapies. Over the past decade, the company has strategically expande... -
Biotech Investment News: Johnson & Johnson’s 10-Year Deal Summary & 2025 Update (2015–2025)
Strategic Review: Immunology, Oncology, and Rare Diseases at the Core of J&J’s R&D-Driven Vision Johnson & Johnson (J&J) has strategically expanded into immunology, oncology, and rare diseases by acquiring biotech compani... -
Biotech Investment News: Merck’s Major Deals from 2015 to 2025
Strategic Review: Beyond Keytruda—Pivot to Next-Gen Modalities Merck (MSD in the U.S.) built a strong oncology franchise with Keytruda. As patents expire, Merck is investing in ADCs, RNA therapies, cell therapy, and precision immunology ... -
Biotech Investment News: Pfizer’s Major Deals Over the Last Decade (2015–2025)
Strategic Review: From mRNA Success to Diversification in Rare Diseases, ADCs, and RNA Editing Pfizer strengthened its biopharmaceutical base with the acquisition of Hospira and GSK’s vaccine assets in 2015, followed by a major expansion... -
[US Research Life & Career Series #2] Three Mindsets to Prepare Before Starting Research in the U.S.
Research life in the U.S. offers diversity, dynamism, and a global environment. Surrounded by cutting-edge technologies and stimulating discussions, you’ll grow tremendously. But before jumping in, having the right mindset can make all t... -
[Science News] Long-Term Latency of Highly Mutated Cells in Esophageal Squamous Cell Carcinoma: Cancer Discovery Summary (With My Thoughts)
A study published in the June 2025 issue of Cancer Discovery reveals that highly mutated cell clones carrying multiple driver mutations can persist for many years in esophageal squamous epithelium before progressing to esophageal squamou... -
Rare & Pediatric Disease News Vol.2: How Far Can Japan Catch Up in Pediatric Rare Disease Drug Development?
– Global Comparison and Future Perspectives in the Post-PRV Era – With the expiration of the U.S. FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program in 2024, a global debate has emerged about how to sustain innovation in ...